PBAC's latest decision on Auranofin: Recommended with restriction (2017). Considered for Alternative capsule formulation of auranofin for patients with rheumatoid arthritis, particularly those with early or mild disease, or those with suboptimal response to methotrexate.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
2
first 2016
Submissions
2
2016 → 2017
Eligible population
Patients with rheumatoid arthritis currently treated with or requiring auranofin, particularly those with early or mild disease or suboptimal response to methotrexate.
Therapy area
Rheumatology
Line of therapy
Any
Evidence base
Cost-minimisation
Economic model
BIA only
ICER note
Not modelled; this is a minor submission for a formulation change (capsule replacing tablet) due to supply shortage.
Submission history
Jul 2016: Recommended with restriction · Unrestricted
Jul 2017: Recommended with restriction · Restricted